Deaf Toddler Hears Mom Say 'I Love You' After Gene Therapy

Travis Smith spent the first years of his life in silence, unable to hear his mother Sierra tell him she loved him or even respond to his own name.

Last week, everything changed. At a White House event on Thursday, President Trump highlighted the toddler's transformation after receiving Regeneron's newly approved gene therapy treatment called Otarmeni. Travis can now hear, dance to music, and experience sounds most of us take for granted.

"He didn't know his name. He couldn't hear me tell him how much I love him," Sierra told the gathering. "And now with Regeneron and this amazing surgery, he can listen to music. And he loves it. And he loves to dance."

The FDA gave accelerated approval for Otarmeni, marking a major milestone in treating congenital deafness. The treatment involves a surgical procedure similar to cochlear implantation and works by delivering gene therapy directly into the inner ear. Because it can be used in young infants, children like Travis can gain hearing during critical early development years.

Regeneron announced the treatment will be provided free of charge to clinically eligible individuals in the U.S. Families may still face costs for the surgical administration itself, which must be performed by surgeons specially trained in the procedure. Parents should check with their healthcare providers about potential out-of-pocket expenses.

Why This Inspires

Travis's story represents more than one family's joy. It signals a new era where genetic conditions once considered permanent can now be treated at their root cause. Gene therapy for deafness was purely theoretical just years ago, and now toddlers are dancing to music they could never have heard without it.

The FDA's accelerated approval process helped bring this treatment to families faster than traditional timelines would allow. When life-changing therapies show promise, speed matters for children whose brains are still developing language and sound processing abilities.

During the event, Trump noted that 17 of the world's largest pharmaceutical companies have now agreed to provide medications at heavily discounted prices to American patients, representing 80% of the branded drug market.

For Sierra Smith, the agreements and approvals translate to something simple and profound: her son knows his name when she calls it.